News & Events

Learn about what's new with CMC Biologics

AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics

News

BOTHELL, Wash., BERKLEY, Calif., COPENHAGEN, DK, HEIDELBERG, DE, CHIBA & YOKOHAMA, JAPAN ─ January 8, 2018 ─ AGC Biologics, a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics, announced today that effective January 8, 2018, the company will be integrated and newly branded as 
AGC Biologics.

CMC Biologics Announces Development and Manufacturing Agreement with Harpoon Therapeutics

News

BOTHELL, Wash., BERKELEY, Calif., and SOUTH SAN FRANCISCO, Calif., USA -- December 12, 2017 -- CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Harpoon Therapeutics, an immuno-oncology company using its proprietary TriTAC™ technology platform to discover and develop novel biologics for the treatment of cancer, announced today they have entered into an agreement for the development and manufacturing of HPN424, HPN536, and HPN217, representing three TriTAC™ molecules for the treatment of various human cancers.

CMC Biologics and Aptevo Therapeutics Enter into Commercial Manufacturing Agreement for IXINITY®

News

Bothell, WA and Seattle, WA – August 22, 2017 – CMC ICOS Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and Aptevo Therapeutics (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, announced today that they have entered into an agreement for the continued commercial manufacture of Aptevo’s factor IX therapeutic, IXINITY® Coagulation Factor IX (Recombinant). 

CMC Biologics Enters into Development and Manufacturing Agreement with Trellis BioScience

News

Development of Trellis’ monoclonal antibody (mAb) using CMC Biologics’ proprietary CHEF1® Expression Platform and Multi-column Continuous Chromatography (MCC) Technology

 

 

Altor BioScience and CMC Biologics Announce Agreement for Manufacture and Validation of Altor’s IL-15 Superagonist Molecule, ALT-803, for use in Phase 3 Clinical Trials

News

BOTHELL, Washington and MIRAMAR, Florida, U.S.A., April 13, 2017—CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Altor BioScience Corporation (“Altor”), a leading developer of novel cytokine-based immunotherapeutics for cancer and infectious diseases, today announced that they have entered into a manufacturing agreement for the cGMP manufacturing of Altor’s ALT-803 molecule for use in Phase 3 clinical trials.

View or Download as a PDF  

CMC Biologics and Genexine Announce Manufacturing Agreement for Genexine's Human Growth Hormone Drug, GX-H9

News

----_Genexine_Logo.jpgBOTHELL, Washington, U.S.A., and SEONGNAM, Republic of Korea, February 21, 2017 - CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Genexine, Inc. (KOSDAQ: 095700), an innovative biotechnology company focused on immuno-oncology, metabolic and orphan diseases, today announced that they have entered into a manufacturing agreement for the process transfer and cGMP manufacturing of Genexine’s GX-H9.

View or Download as a PDF  

CMC Biologics Enters into Manufacturing Agreement with CytoDyn

News

Agreement covers process development and manufacture of CytoDyn’s PRO 140

 


Bothell, WA, Copenhagen, Denmark, Berkeley, CA, and Tokyo, Japan– February 15, 2017
 –CMC Biologics, a
 global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and CytoDyn Inc., a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection, announced today they have entered into an agreement for the process development and commercial manufacture of CytoDyn’s PRO 140.

View or Download as a PDF  

AGC Asahi Glass Signs Agreement to Acquire CMC Biologics

News

CMC Biologics to continue to provide CDMO services to the biopharma marketplace

 

Bothell, WA, Copenhagen, Denmark, Berkeley, CA, and Tokyo, Japan– December 19, 2016 – CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins and AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, announced today that they have entered into a definitive agreement with CMC Biologics’ shareholders including Monitor Clipper Partners, European Equity Partners and Innoven Partenaires, by which AGC will acquire 100% of CMC Biologics’ shares. This acquisition is expected to close in January 2017. 

View or Download as a PDF  

CMC Biologics Participates in Denmark State Visit to Korea

News

CMC Biologics Copenhagen Facility site head Patricio Massera, was honored to participate in the recent Danish State Visit to Korea

CMC Biologics was chosen for inclusion in the state visit, along with representatives from other select Danish companies in the Health Industry, for participation in a Denmark- Korea Roundtable Meeting on Health.

CMC Biologics and IDT Biologika Announce the Addition of Cerbios-Pharma and Oncotec Pharma to their Strategic Collaboration

News

Cerbios-Pharma will Provide Highly Cytotoxic Drug Payloads and Conjugation Services for Manufacture of ADC Drug Substance

Oncotec Pharma will Provide Sterile Filling and Lyophilization of Cytotoxic Active Ingredients for ADCs
Follow Us
Join us on LinkedIn Follow us on Twitter